|
1
|
Schuster SJ, Dickinson M, Dreyling M, Martinez‐Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Abdelhady A, Zia A, Morisse MC, Fowler NH, Thieblemont C. EFFICACY AND SAFETY OF TISAGENLECLEUCEL (TISA‐CEL) IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): PRIMARY ANALYSIS OF THE PHASE 2 ELARA TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.85_2879] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S. J. Schuster
- Perelman Center for Advanced Medicine University of Pennsylvania Philadelphia USA
| | - M. Dickinson
- Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Australia
| | - M. Dreyling
- Medizinische Klinik III, LMU Klinikum Munich Germany
| | - J. Martinez‐Lopez
- Hospital 12 De Octubre Madrid Complutense University CNIO Madrid Spain
| | - A. Kolstad
- Department of Oncology Oslo University Hospital Oslo Norway
| | - J. Butler
- Haematology and Bone Marrow Transplantation Royal Brisbane Hospital Herston Australia
| | - M. Ghosh
- Department of Internal Medicine Michigan Medicine University of Michigan Ann Arbor USA
| | - L. Popplewell
- Department of Hematology & Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte USA
| | - J. C. Chavez
- Department of Malignant Hematology Moffitt Cancer Center Tampa USA
| | - E. Bachy
- Department of Hematology Hospices Civils de Lyon and Université Claude Bernard Lyon 1 Lyon France
| | - K. Kato
- Department of Hematology Kyushu University Hospital Fukuoka Japan
| | - H. Harigae
- Department of Hematology Tohoku University Hospital Sendai Japan
| | - M. José Kersten
- Cancer Center Amsterdam Amsterdam UMC University of Amsterdam on behalf of HOVON/LLPC Amsterdam Netherlands
| | - C. Andreadis
- Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco USA
| | - P. A. Riedell
- Department of Medicine University of Chicago Chicago USA
| | - A. Abdelhady
- Oncology Novartis Pharmaceuticals Corporation East Hanover USA
| | - A. Zia
- Biostatistics Novartis Pharma AG Basel Switzerland
| | - M. C. Morisse
- Oncology Novartis Pharmaceuticals Corporation East Hanover USA
| | - N. H. Fowler
- MD Anderson Cancer Center The University of Texas MD Anderson Cancer Center Houston Texas USA
| | - C. Thieblemont
- Department of Hemato‐Oncology Hôpital Saint‐Louis‐Université de Paris Paris France
| |
Collapse
|
|
2
|
Fowler NH, Dickinson M, Martinez‐Lopez J, Kolstad A, Schuster SJ, Dreyling M, Ghosh M, Harigae H, Kersten MJ, Bachy E, Popplewell L, Chavez JC, Ho PJ, Butler J, Kato K, Tresckow B, Ferreri AJM, Simón JAP, Patten PEM, Andreadis C, Riedell PA, McGuirk JP, Nastoupil LJ, Teshima T, Offner F, Petzer A, Viardot A, Zinzani PL, Malladi R, Zhang J, Tiwari R, Bollu V, Masood A, Thieblemont C. PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLECLEUCEL (TISA‐CEL) INFUSION IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL). Hematol Oncol 2021. [DOI: 10.1002/hon.178_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- N. H. Fowler
- The University of Texas MD Anderson Cancer Center Department of Lymphoma‐Myeloma Houston Texas USA
| | - M. Dickinson
- Royal Melbourne Hospital Peter MacCallum Cancer Centre Melbourne Australia
| | | | - A. Kolstad
- Oslo University Hospital Department of Oncology Oslo Norway
| | - S. J. Schuster
- University of Pennsylvania Lymphoma Program Philadelphia Pennsylvania USA
| | - M. Dreyling
- LMU Klinikum Medizinische Klinik III Munich Germany
| | - M. Ghosh
- University of Michigan Michigan Medicine Ann Arbor Michigan USA
| | - H. Harigae
- Tohoku University Hospital Department of Hematology and Rheumatology Sendai Japan
| | - M. José Kersten
- Amsterdam UMC University of Amsterdam on behalf of HOVON/LLPC Department of Hematology Amsterdam Netherlands
| | - E. Bachy
- Université Claude Bernard Lyon 1 Hospices Civils de Lyon Lyon France
| | - L. Popplewell
- City of Hope National Medical Center Department of Hematology & Hematopoietic Cell Transplantation Duarte California USA
| | - J. C. Chavez
- Moffitt Cancer Center Department of Malignant Hematology Tampa Florida USA
| | - P. J. Ho
- Royal Prince Alfred Hospital and University of Sydney Institute of Haematology Camperdown Australia
| | - J. Butler
- Royal Brisbane Hospital Haematology and Bone Marrow Transplant Unit Herston Australia
| | - K. Kato
- Kyushu University Hospital Hematology, Oncology, & Cardiovascular Medicine Fukuoka Japan
| | - B. Tresckow
- University Hospital Essen University of Duisburg‐Essen Clinic for Hematology and Stem Cell Transplantation West German Cancer Center Essen Germany
| | - A. J. M. Ferreri
- IRCCS Ospedale San Raffaele Department of Onco‐hematology Milan Italy
| | - J. A. P. Simón
- University Hospital Virgen del Rocío Instituto de Biomedicina de Sevilla (IBIS / CSIC / CIBERONC) Universidad de Sevilla Department of Hematology Sevilla Spain
| | - P. E. M. Patten
- King’s College Hospital and King’s College London Division of Cancer Studies London UK
| | - C. Andreadis
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco California USA
| | - P. A. Riedell
- University of Chicago Medical Center Department of Medicine Chicago Illinois USA
| | - J. P. McGuirk
- University of Kansas Medical Center Division of Hematologic Malignancies and Cellular Therapeutics Kansas City Kansas USA
| | - L. J. Nastoupil
- The University of Texas MD Anderson Cancer Center Department of Lymphoma‐Myeloma Houston Texas USA
| | - T. Teshima
- Hokkaido University Hospital Department of Hematology Sapporo Japan
| | - F. Offner
- UZ Gent Department of Hematology Gent Belgium
| | - A. Petzer
- Ordensklinikum Linz GmbH Elisabethinen Internal Medicine I Linz Austria
| | - A. Viardot
- University Hospital of Ulm Department of Internal Medicine III Ulm Germany
| | - P. L. Zinzani
- University of Bologna Institute of Hematology “Seràgnoli” Bologna Italy
| | - R. Malladi
- Cambridge University Hospitals NHS Foundation Trust Centre for Clinical Haematology Cambridge UK
| | - J. Zhang
- Novartis Pharmaceuticals Corporation Global Value and Access East Hanover New Jersey USA
| | - R. Tiwari
- Novartis Healthcare Pvt. Ltd Biostatistics Hyderabad India
| | - V. Bollu
- Novartis Pharmaceuticals Corporation Health Economics and Outcomes Research East Hanover New Jersey USA
| | - A. Masood
- Novartis Pharmaceuticals Corporation Clinical Development East Hanover New Jersey USA
| | - C. Thieblemont
- Hôpital Saint‐Louis‐Université de Paris Service d'Hématologie‐Oncologie Paris France
| |
Collapse
|